Statements issued by the BHVS

Statements issued by the BHVS, sometimes as a Joint Statement with other professional medical societies, in response to important issues concerning patients with heart valve disease.

Statement on the NICE Guideline on Heart Valve Disease

BHVS has produced a formal response to the publication of the NICE guideline 208 on the investigation and management of adult patients presenting with heart valve disease. We highlight strengths and weaknesses of the guidance and summarize the key new recommendations.

Warfarin 5mg tablets and 3mg tablets

Anticoagulation for patients with mechanical heart valves

BHVS is delighted to have collaborated with the British Cardiovascular Society (BCS), Society for Cardiothoracic Surgery (SCTS), British Congenital Cardiac Association (BCCA), British Society of Echocardiography (BSE) and the Primary Care Cardiovascular Society (PCCS) to produce a Joint Statement on the topic of anticoagulation in patients with mechanical heart valves, following the National Patient Safety Alert issued last month by NHS England.

Enhanced follow-up for patients with Trifecta aortic replacement valves

BHVS is delighted to have collaborated with the British Cardiovascular Society (BCS) and the Society for Cardiothoracic Surgery (SCTS) to produce a Joint Statement regarding enhanced follow-up for patients with a Trifecta aortic valve replacement, following an advisory safety warning issued in summer 2020 by the Medicines and Health Regulatory Authority (MHRA).